While these drugs are highly effective for weight loss and glycemic control, they are associated with gastrointestinal issues such as nausea, vomiting, and diarrhea, which can lead to treatment discontinuation among some patients For instance, clinical data and patient reports have shown that adverse events are particularly common during the early stages of treatment with drugs such as semaglutide and tirzepatide, prompting careful dose titration and medical supervision, which may not be feasible for all patients or healthcare settings Addressing these side effect concerns through better patient education, physician training, and next-generation formulations with reduced tolerability issues is crucial to improving long-term adherence and treatment outcomes
Ask your primary care physician , if you have one
While these drugs are generally considered safe to take in tandem, following specific guidelines ensures that both remain effective
Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men
When used correctly, CJC 1295 Ipamorelin is generally safe